Table of Contents Author Guidelines Submit a Manuscript
AIDS Research and Treatment
Volume 2012 (2012), Article ID 751827, 14 pages
http://dx.doi.org/10.1155/2012/751827
Review Article

Alcohol Consumption, Progression of Disease and Other Comorbidities, and Responses to Antiretroviral Medication in People Living with HIV

1Departments of Pharmacology & Toxicology and Global Health, University of Toronto, Toronto, ON, Canada M5S 1A1
2In Vitro Drug Safety and Biotechnology, MaRS Discovery District, 101 College Street, Suite 300, Lab 351, Toronto, ON, Canada M5G 1L7
3Institute of Drug Research, Canada
4Alcohol and Drug Abuse Research Unit, South African Medical Research Council, Cape Town-Tygerberg 7505, South Africa
5Department of Psychiatry, Stellenbosch University, Cape Town-Tygerberg 7505, South Africa

Received 6 September 2011; Revised 13 December 2011; Accepted 2 January 2012

Academic Editor: Frederick L. Altice

Copyright © 2012 Manuela G. Neuman et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. Pithey and C. Parry, “Descriptive systematic review of sub-Saharan African studies on the association between alcohol use and HIV infection,” SAHARA-J, vol. 6, no. 4, pp. 155–169, 2009. View at Google Scholar · View at Scopus
  2. J. Rehm and C. D. Parry, “Alcohol consumption and infectious diseases in South Africa,” The Lancet, vol. 374, no. 9707, p. 2053, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. G. Neuman, M. Monteiro, and J. Rehm, “Drug interactions between psychoactive substances and antiretroviral therapy in individuals infected with human immunodeficiency and hepatitis viruses,” Substance Use and Misuse, vol. 41, no. 10–12, pp. 1395–1463, 2006. View at Publisher · View at Google Scholar · View at Scopus
  4. M. Núñez, “Hepatotoxicity of antiretrovirals: incidence, mechanisms and management,” Journal of Hepatology, vol. 44, no. 1, pp. S132–S139, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. S. Barve, R. Kapoor, A. Moghe et al., “Focus on the liver: alcohol use, highly active antiretroviral therapy, and liver disease in HIV infected patients,” Alcohol Research and Health, vol. 33, no. 3, pp. 229–236, 2010. View at Google Scholar · View at Scopus
  6. J. Rehm, A. V. Samokhvalov, M. G. Neuman et al., “The association between alcohol use, alcohol use disorders and tuberculosis (TB). A systematic review,” BMC Public Health, vol. 9, article 450, 2009. View at Publisher · View at Google Scholar · View at Scopus
  7. D. Quintero and D. M. Guidot, “Focus on the lung,” Alcohol Research and Health, vol. 33, no. 3, pp. 219–228, 2010. View at Google Scholar · View at Scopus
  8. M. S. Freiberg and K. L. Kraemer, “Focus on the heart: alcohol consumption, HIV infection, and cardiovascular disease,” Alcohol Research and Health, vol. 33, no. 3, pp. 237–246, 2010. View at Google Scholar · View at Scopus
  9. M. J. Rosenbloom, E. V. Sullivan, and A. Pfefferbaum, “Focus on the brain: HIV infection and alcoholism comorbidity effects on brain structure and function,” Alcohol Research and Health, vol. 33, no. 3, pp. 247–257, 2010. View at Google Scholar · View at Scopus
  10. C. S. Lieber, “Alcohol and the liver: 1994 update,” Gastroenterology, vol. 106, no. 4, pp. 1085–1105, 1994. View at Google Scholar · View at Scopus
  11. A. A. Chaudhry, M. S. Sulkowski, G. Chander, and R. D. Moore, “Hazardous drinking is associated with an elevated aspartate aminotransferase to platelet ratio index in an urban HIV-infected clinical cohort,” HIV Medicine, vol. 10, no. 3, pp. 133–142, 2009. View at Publisher · View at Google Scholar · View at Scopus
  12. V. L. Vecchi, M. Soresi, C. Colomba et al., “Transient elastography: a non-invasive tool for assessing liver fibrosis in HIV/HCV patients,” World Journal of Gastroenterology, vol. 16, no. 41, pp. 5225–5232, 2010. View at Publisher · View at Google Scholar · View at Scopus
  13. E. Rosenthal, G. Pialoux, N. Bernard et al., “Liver-related mortality in human-immunodeficiency-virusinfected patients between 1995 and 2003 in the French GERMIVIC joint study group network (MORTAVIC 2003 study),” Journal of Viral Hepatitis, vol. 14, no. 3, pp. 183–188, 2007. View at Publisher · View at Google Scholar · View at Scopus
  14. E. Rosenthal, D. Salmon-Céron, C. Lewden et al., “Liver-related deaths in HIV-infected patients between 1995 and 2005 in the French GERMIVIC Joint Study Group Network (Mortavic 2005 Study in collaboration with the Mortalité 2005 survey, ANRS EN19),” HIV Medicine, vol. 10, no. 5, pp. 282–289, 2009. View at Publisher · View at Google Scholar · View at Scopus
  15. S. Pol, B. Lamorthe, N. T. Thi et al., “Retrospective analysis of the impact of HIV infection and alcohol use on chronic hepatitis C in a large cohort of drug users,” Journal of Hepatology, vol. 28, no. 6, pp. 945–950, 1998. View at Publisher · View at Google Scholar · View at Scopus
  16. C. Castellares, P. Barreiro, L. Martín-Carbonero et al., “Liver cirrhosis in HIV-infected patients: prevalence, aetiology and clinical outcome,” Journal of Viral Hepatitis, vol. 15, no. 3, pp. 165–172, 2008. View at Publisher · View at Google Scholar · View at Scopus
  17. R. Lana, M. Núñez, J. L. Mendoza, and V. Soriano, “Rate and risk factors of liver toxicity in patients receiving antiretroviral therapy,” Medicina Clinica, vol. 117, no. 16, pp. 607–610, 2001. View at Google Scholar · View at Scopus
  18. M. G. Neuman, “Cytokines—central factors in alcoholic liver disease,” Alcohol Research and Health, vol. 27, no. 4, pp. 307–316, 2003. View at Google Scholar · View at Scopus
  19. M. G. Neuman, “Apoptosis in diseases of the liver,” Critical Reviews in Clinical Laboratory Sciences, vol. 38, no. 2, pp. 109–166, 2001. View at Google Scholar · View at Scopus
  20. M. J. Míguez-Burbano, J. E. Lewis, and R. Malow, “Alcohol and race/ethnicity elicit different changes in lipid profiles in HIV-infected individuals receiving highly active antiretroviral therapy,” Journal of the Association of Nurses in AIDS Care, vol. 20, no. 3, pp. 176–183, 2009. View at Publisher · View at Google Scholar · View at Scopus
  21. D. M. Murdoch, S. Napravnik, J. J. Eron Jr., and A. van Rie, “Smoking and predictors of pneumonia among HIV-infected patients receiving care in the HAART era,” The Open Respiratory Medicine Journal, vol. 2, pp. 22–28, 2008. View at Google Scholar
  22. I. Grau, R. Pallares, F. Tubau et al., “Epidemiologic changes in bacteremic pneumococcal disease in patients with human immunodeficiency virus in the era of highly active antiretroviral therapy,” Archives of Internal Medicine, vol. 165, no. 13, pp. 1533–1540, 2005. View at Publisher · View at Google Scholar · View at Scopus
  23. I. Corral, C. Quereda, A. Moreno et al., “Cerebrovascular ischemic events in HIV-1-infected patients receiving highly active antiretroviral therapy: incidence and risk factors,” Cerebrovascular Diseases, vol. 27, no. 6, pp. 559–563, 2009. View at Publisher · View at Google Scholar · View at Scopus
  24. R. J. Ellis, D. Rosario, D. B. Clifford et al., “Continued high prevalence and adverse clinical impact of human immunodeficiency virus-associated sensory neuropathy in the era of combination antiretroviral therapy: the CHARTER study,” Archives of Neurology, vol. 67, no. 5, pp. 552–558, 2010. View at Publisher · View at Google Scholar · View at Scopus
  25. M. K. Baum, C. Rafie, S. Lai, S. Sales, J. B. Page, and A. Campa, “Alcohol use accelerates HIV disease progression,” AIDS Research and Human Retroviruses, vol. 26, no. 5, pp. 511–518, 2010. View at Publisher · View at Google Scholar
  26. R. Fama, J. C. Eisen, M. J. Rosenbloom et al., “Upper and lower limb motor impairments in alcoholism, HIV infection, and their comorbidity,” Alcoholism: Clinical & Experimental Research, vol. 31, no. 6, pp. 1038–1044, 2007. View at Publisher · View at Google Scholar · View at Scopus
  27. R. Fama, M. J. Rosenbloom, B. N. Nichols, A. Pfefferbaum, and E. V. Sullivan, “Working and episodic memory in HIV infection, alcoholism, and their comorbidity: baseline and 1-year follow-up examinations,” Alcoholism: Clinical & Experimental Research, vol. 33, no. 10, pp. 1815–1824, 2009. View at Publisher · View at Google Scholar · View at Scopus
  28. G. Madeddu, E. M. Porqueddu, F. Cambosu et al., “Bacterial community acquired pneumonia in HIV-infected inpatients in the highly active antiretroviral therapy era,” Infection, vol. 36, no. 3, pp. 231–236, 2008. View at Publisher · View at Google Scholar · View at Scopus
  29. N. Crum-Cianflone, G. Collins, S. Medina et al., “Prevalence and factors associated with liver test abnormalities among human immunodeficiency virus-infected persons,” Clinical Gastroenterology and Hepatology, vol. 8, no. 2, pp. 183–191, 2010. View at Publisher · View at Google Scholar · View at Scopus
  30. M. A. Loko, D. Salmon, P. Carrieri et al., “The French national prospective cohort of patients co-infected with HIV and HCV (ANRS CO13 HEPAVIH): early findings, 2006–2010,” BMC Infectious Diseases, vol. 10, article 303, 2010. View at Publisher · View at Google Scholar · View at Scopus
  31. T. J. Henrich, N. Lauder, M. M. Desai, and A. N. Sofair, “Association of alcohol abuse and injection drug use with immunologic and virologic responses to HAART in HIV-positive patients from urban community health clinics,” Journal of Community Health, vol. 33, no. 2, pp. 69–77, 2008. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Pol, “Improvement of the CD4 cell count after alcohol withdrawal in HIV-positive alcoholic patients,” AIDS, vol. 10, no. 11, pp. 1293–1294, 1996. View at Google Scholar · View at Scopus
  33. M. J. Miguez, G. Shor-Posner, G. Morales, A. Rodriguez, and X. Burbano, “HIV treatment in drug abusers: impact of alcohol use,” Addiction Biology, vol. 8, no. 1, pp. 33–37, 2003. View at Publisher · View at Google Scholar · View at Scopus
  34. J. H. Samet, D. M. Cheng, H. Libman, D. P. Nunes, J. K. Alperen, and R. Saitz, “Alcohol consumption and HIV disease progression,” Journal of Acquired Immune Deficiency Syndromes, vol. 46, no. 2, pp. 194–199, 2007. View at Publisher · View at Google Scholar · View at Scopus
  35. M. K. Baum, C. Rafie, S. Lai, S. Sales, J. B. Page, and A. Campa, “Alcohol use accelerates HIV disease progression,” AIDS Research and Human Retroviruses, vol. 26, no. 5, pp. 511–518, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. E. Shacham, A. Agbebi, K. Stamm, and E. T. Overton, “Alcohol consumption is associated with poor health in HIV clinic patient population: a behavioral surveillance study,” AIDS and Behavior, vol. 15, no. 1, pp. 209–213, 2009. View at Publisher · View at Google Scholar · View at Scopus
  37. M. J. Míguez-Burbano, J. E. Lewis, J. Fishman, D. Asthana, and R. M. Malow, “The influence of different types of alcoholic beverages on disrupting highly active antiretroviral treatment (HAART) outcome,” Alcohol and Alcoholism, vol. 44, no. 4, pp. 366–371, 2009. View at Publisher · View at Google Scholar · View at Scopus
  38. N. A. Hessol, A. Kalinowski, L. Benning et al., “Mortality among participants in the Multicenter AIDS Cohort Study and the Women's Interagency HIV Study,” Clinical Infectious Diseases, vol. 44, no. 2, pp. 287–294, 2007. View at Publisher · View at Google Scholar · View at Scopus
  39. R. S. Braithwaite, J. Conigliaro, M. S. Roberts et al., “Estimating the impact of alcohol consumption on survival for HIV+ individuals,” AIDS Care, vol. 19, no. 4, pp. 459–466, 2007. View at Publisher · View at Google Scholar · View at Scopus
  40. G. K. Robbins, K. L. Johnson, Y. Chang et al., “Predicting virologic failure in an HIV clinic,” Clinical Infectious Diseases, vol. 50, no. 5, pp. 779–786, 2010. View at Publisher · View at Google Scholar · View at Scopus
  41. C. S. Hendershot, S. A. Stoner, D. W. Pantalone, and J. M. Simoni, “Alcohol use and antiretroviral adherence: review and meta-analysis,” Journal of Acquired Immune Deficiency Syndromes, vol. 52, no. 2, pp. 180–202, 2009. View at Publisher · View at Google Scholar · View at Scopus
  42. S. Naar-King, C. Arfken, M. Frey, M. Harris, E. Secord, and D. Ellis, “Psychosocial factors and treatment adherence in paediatric HIV/AIDS,” AIDS Care, vol. 18, no. 6, pp. 621–628, 2006. View at Publisher · View at Google Scholar · View at Scopus
  43. M. M. Finucane, J. H. Samet, and N. J. Horton, “Translational methods in biostatistics: linear mixed effect regression models of alcohol consumption and HIV disease progression over time,” Epidemiologic Perspectives and Innovations, vol. 4, article 8, 2007. View at Publisher · View at Google Scholar · View at Scopus
  44. M. Lazo, S. J. Gange, T. E. Wilson et al., “Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women,” Clinical Infectious Diseases, vol. 45, no. 10, pp. 1377–1385, 2007. View at Publisher · View at Google Scholar · View at Scopus
  45. A. Sankar, T. Wunderlich, S. Neufeld, and M. Luborsky, “Sero-positive African Americans' beliefs about alcohol and their impact on anti-retroviral adherence,” AIDS and Behavior, vol. 11, no. 2, pp. 195–203, 2007. View at Publisher · View at Google Scholar · View at Scopus
  46. P. S. Sullivan, M. L. Campsmith, G. V. Nakamura, E. B. Begley, J. Schulden, and A. K. Nakashima, “Patient and regimen characteristics associated with self-reported nonadherence to antiretroviral therapy,” PLoS ONE, vol. 2, no. 6, Article ID e552, 2007. View at Publisher · View at Google Scholar · View at Scopus
  47. J. Leserman, G. Ironson, C. O'Cleirigh, J. M. Fordiani, and E. Balbin, “Stressful life events and adherence in HIV,” AIDS Patient Care and STDs, vol. 22, no. 5, pp. 403–411, 2008. View at Publisher · View at Google Scholar · View at Scopus
  48. J. T. Parsons, E. Rosof, and B. Mustanski, “Medication adherence mediates the relationship between adherence self-efficacy and biological assessments of HIV health among those with alcohol use disorders,” AIDS and Behavior, vol. 12, no. 1, pp. 95–103, 2008. View at Publisher · View at Google Scholar · View at Scopus
  49. M. Plankey, P. Bacchetti, C. Jin et al., “Self-perception of body fat changes and HAART adherence in the women's interagency HIV study,” AIDS and Behavior, vol. 13, no. 1, pp. 53–59, 2009. View at Publisher · View at Google Scholar · View at Scopus
  50. A. J. Applebaum, M. A. Richardson, S. M. Brady, D. J. Brief, and T. M. Keane, “Gender and other psychosocial factors as predictors of adherence to highly active antiretroviral therapy (HAART) in adults with comorbid HIV/AIDS, psychiatric and substance-related disorder,” AIDS and Behavior, vol. 13, no. 1, pp. 60–65, 2009. View at Publisher · View at Google Scholar · View at Scopus
  51. K. Arasteh and D. C. Des Jarlais, “HIV testing and treatment among at-risk drinking injection drug users,” Journal of the International Association of Physicians in AIDS Care, vol. 8, no. 3, pp. 196–201, 2009. View at Publisher · View at Google Scholar · View at Scopus
  52. S. C. Kalichman, C. M. Amaral, D. White et al., “Prevalence and clinical implications of interactive toxicity beliefs regarding mixing alcohol and antiretroviral therapies among people living with HIV/AIDS,” AIDS Patient Care and STDs, vol. 23, no. 6, pp. 449–454, 2009. View at Publisher · View at Google Scholar · View at Scopus
  53. R. Kavasery, N. Galai, J. Astemborski et al., “Nonstructured treatment interruptions among injection drug users in Baltimore, MD,” Journal of Acquired Immune Deficiency Syndromes, vol. 50, no. 4, pp. 360–366, 2009. View at Publisher · View at Google Scholar · View at Scopus
  54. M. Lillie-Blanton, V. E. Stone, A. Snow Jones et al., “Association of race, substance abuse, and health insurance coverage with use of highly active antiretroviral therapy among HIV-infected women, 2005,” American Journal of Public Health, vol. 100, no. 8, pp. 1493–1499, 2010. View at Publisher · View at Google Scholar · View at Scopus
  55. K. Lehavot, D. Huh, K. L. Walters, K. M. King, M. P. Andrasik, and J. M. Simoni, “Buffering effects of general and medication-specific social support on the association between substance use and HIV medication adherence,” AIDS Patient Care and STDs, vol. 25, no. 3, pp. 181–189, 2011. View at Publisher · View at Google Scholar
  56. B. Spire, S. Duran, M. Souville, C. Leport, F. Raffi, and J. P. Moatti, “Adherence to highly active antiretroviral therapies (HAART) in HIV-infected patients: from a predictive to a dynamic approach,” Social Science and Medicine, vol. 54, no. 10, pp. 1481–1496, 2002. View at Publisher · View at Google Scholar · View at Scopus
  57. P. Roux, M. P. Carrieri, V. Villes et al., “The impact of methadone or buprenorphine treatment and ongoing injection on highly active antiretroviral therapy (HAART) adherence: evidence from the MANIF2000 cohort study,” Addiction, vol. 103, no. 11, pp. 1828–1836, 2008. View at Publisher · View at Google Scholar · View at Scopus
  58. C. Protopopescu, F. Raffi, P. Roux et al., “Factors associated with non-adherence to long-term highly active antiretroviral therapy: a 10 year follow-up analysis with correction for the bias induced by missing data,” Journal of Antimicrobial Chemotherapy, vol. 64, no. 3, pp. 599–606, 2009. View at Publisher · View at Google Scholar · View at Scopus
  59. L. Michel, M. P. Carrieri, L. Fugon et al., “Harmful alcohol consumption and patterns of substance use in HIV-infected patients receiving antiretrovirals (ANRS-EN12-VESPA Study): relevance for clinical management and intervention,” AIDS Care, vol. 22, no. 9, pp. 1136–1145, 2010. View at Publisher · View at Google Scholar · View at Scopus
  60. T. R. Glass, M. Battegay, M. Cavassini et al., “Longitudinal analysis of patterns and predictors of changes in self-reported adherence to antiretroviral therapy: swiss HIV cohort study,” Journal of Acquired Immune Deficiency Syndromes, vol. 54, no. 2, pp. 197–203, 2010. View at Publisher · View at Google Scholar · View at Scopus
  61. B. Södergård, M. Halvarsson, M. P. Tully et al., “Adherence to treatment in Swedish HIV-infected patients,” Journal of Clinical Pharmacy and Therapeutics, vol. 31, no. 6, pp. 605–616, 2006. View at Publisher · View at Google Scholar · View at Scopus
  62. J. Grierson, R. L. Koelmeyer, A. Smith, and M. Pitts, “Adherence to antiretroviral therapy: factors independently associated with reported difficulty taking antiretroviral therapy in a national sample of HIV-positive Australians,” HIV Medicine, vol. 12, no. 9, pp. 562–569, 2011. View at Publisher · View at Google Scholar
  63. J. B. Nachega, A. R. Knowlton, A. Deluca et al., “Treatment supporter to improve adherence to antiretroviral therapy in HIV-infected South African adults: a qualitative study,” Journal of Acquired Immune Deficiency Syndromes, vol. 43, supplement 1, pp. S127–S133, 2006. View at Publisher · View at Google Scholar · View at Scopus
  64. M. Fitzgerald, M. Collumbien, and V. Hosegood, “No one can ask me “Why do you take that stuff?”: men's experiences of antiretroviral treatment in South Africa,” AIDS Care, vol. 22, no. 3, pp. 355–360, 2010. View at Publisher · View at Google Scholar · View at Scopus
  65. H. B. Jaspan, A. D. Mueller, L. Myer, L.-G. Bekker, and C. Orrell, “Effect of caregivers' depression and alcohol use on child antiretroviral adherence in South Africa,” AIDS Patient Care and STDs, vol. 25, no. 10, pp. 595–600, 2011. View at Publisher · View at Google Scholar
  66. R. Manfredi and L. Calza, “HIV infection and the pancreas: risk factors and potential management guidelines,” International Journal of STD & AIDS, vol. 19, no. 2, pp. 99–105, 2008. View at Publisher · View at Google Scholar
  67. K. A. Beyene, T. Gedif, T. Gebre-Mariam, and E. Engidawork, “Highly active antiretroviral therapy adherence and its determinants in selected hospitals from south and central Ethiopia,” Pharmacoepidemiology and Drug Safety, vol. 18, no. 11, pp. 1007–1015, 2009. View at Publisher · View at Google Scholar · View at Scopus
  68. N. T. Do, K. Phiri, H. Bussmann, T. Gaolathe, R. G. Marlink, and C. W. Wester, “Psychosocial factors affecting medication adherence among HIV-1 infected adults receiving combination antiretroviral therapy (cART) in Botswana,” AIDS Research and Human Retroviruses, vol. 26, no. 6, pp. 685–691, 2010. View at Publisher · View at Google Scholar · View at Scopus
  69. A. Jaquet, D. K. Ekouevi, J. Bashi et al., “Alcohol use and non-adherence to antiretroviral therapy in HIV-infected patients in West Africa,” Addiction, vol. 105, no. 8, pp. 1416–1421, 2010. View at Publisher · View at Google Scholar · View at Scopus
  70. P. D. F. Bonolo, C. C. César, F. A. Acúrcio et al., “Non-adherence among patients initiating antiretroviral therapy: a challenge for health professionals in Brazil,” AIDS, vol. 19, supplement 4, pp. S5–S13, 2005. View at Google Scholar · View at Scopus
  71. P. De Fátima Bonolo, C. J. Machado, C. C. César, M. D. G. B. Ceccato, and M. D. C. Guimarães, “Vulnerability and non-adherence to antiretroviral therapy among HIV patients, Minas Gerais State, Brazil,” Cadernos de Saude Publica, vol. 24, no. 11, pp. 2603–2613, 2008. View at Google Scholar · View at Scopus
  72. D. Kitkungvan, A. Apisarnthanarak, P. Laowansiri, and L. M. Mundy, “Secure antiretroviral therapy delivery in a resource-limited setting: streamlined to minimize drug resistance and expense,” HIV Medicine, vol. 9, no. 8, pp. 636–641, 2008. View at Publisher · View at Google Scholar · View at Scopus
  73. K. K. Venkatesh, A. K. Srikrishnan, K. H. Mayer et al., “Predictors of nonadherence to highly active antiretroviral therapy among HIV-infected South Indians in clinical care: implications for developing adherence interventions in resource-limited settings,” AIDS Patient Care and STDs, vol. 24, no. 12, pp. 795–803, 2010. View at Publisher · View at Google Scholar · View at Scopus
  74. R. C. Neblett, H. E. Hutton, B. Lau, M. E. McCaul, R. D. Moore, and G. Chander, “Alcohol consumption among HIV-infected women: impact on time to antiretroviral therapy and survival,” Journal of Women's Health, vol. 20, no. 2, pp. 279–286, 2011. View at Publisher · View at Google Scholar
  75. P. N. Halkitis, A. H. Kutnick, and S. Slater, “The social realities of adherence to protease inhibitor regimens: substance use, health care and psychological states,” Journal of Health Psychology, vol. 10, no. 4, pp. 545–558, 2005. View at Publisher · View at Google Scholar · View at Scopus
  76. C. J. Smith, I. Levy, C. A. Sabin, E. Kaya, M. A. Johnson, and M. C. I. Lipman, “Cardiovascular disease risk factors and antiretroviral therapy in an HIV-positive UK population,” HIV Medicine, vol. 5, no. 2, pp. 88–92, 2004. View at Publisher · View at Google Scholar · View at Scopus
  77. I. M. Kigozi, L. M. Dobkin, J. N. Martin et al., “Late-disease stage at presentation to an HIV clinic in the era of free antiretroviral therapy in Sub-Saharan Africa,” Journal of Acquired Immune Deficiency Syndromes, vol. 52, no. 2, pp. 280–289, 2009. View at Publisher · View at Google Scholar · View at Scopus
  78. E. M. Gardner, W. J. Burman, J. F. Steiner, P. L. Anderson, and D. R. Bangsberg, “Antiretroviral medication adherence and the development of class-specific antiretroviral resistance,” AIDS, vol. 23, no. 9, pp. 1035–1046, 2009. View at Publisher · View at Google Scholar · View at Scopus
  79. P. A. Shuper, M. Neuman, F. Kanteres, D. Baliunas, N. Joharchi, and J. Rehm, “Causal considerations on alcohol and HIV/AIDS—a systematic review,” Alcohol and Alcoholism, vol. 45, no. 2, pp. 159–166, 2010. View at Publisher · View at Google Scholar · View at Scopus